Parnax Lab Ltd

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 01 August 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This revision follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, reflecting a cautious stance despite some positive long-term returns.

Parnax Lab Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical outlook and valuation metrics despite flat recent financial performance. The upgrade, effective from 13 July 2026, is driven by a combination of bullish technical indicators, attractive valuation relative to peers, stable financial trends, and a consistent return profile that outpaces broader market benchmarks.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 July 2026. This change reflects a combination of flat recent financial performance, mixed technical indicators, and valuation considerations that collectively weigh on the stock’s near-term outlook despite its strong long-term returns.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 3 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some recent flat quarterly performance. The stock’s recent market-beating returns and enhanced technical outlook have contributed to this reassessment.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a recent downgrade in its Mojo Grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value-oriented investors seeking exposure in this sector.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite achieving record quarterly net sales, the company’s profitability and margin metrics have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 March 2026.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Parnax Lab Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹170.00 crores, reported net profit of ₹2.18 crores for Q4 FY26 (Mar'26 quarter), marking a concerning decline of 19.56% quarter-on-quarter and 25.34% year-on-year. Despite robust revenue growth, the company's profitability came under severe pressure due to margin compression and elevated other income dependency, raising questions about the sustainability of its operational performance.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust long-term return profile, recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of investor sentiment amid broader market dynamics.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair to an attractive valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Hold, signals a potential reappraisal of the stock’s price attractiveness amid improving fundamentals and relative sector comparisons.

Surging from a 52-week low of Rs 87.5 to a fresh peak of Rs 182, Parnax Lab Ltd has delivered an impressive 80.28% return over the past year, significantly outperforming the Sensex which declined by 3.93% during the same period. This milestone comes amid a backdrop of broad technical strength that has propelled the stock higher despite a weakening broader market.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company's performance and outlook.